Repligen Corporation (FRA:RGN)

Germany flag Germany · Delayed Price · Currency is EUR
104.10
-7.85 (-7.01%)
Last updated: Apr 23, 2026, 8:04 AM CET
Market Cap5.49B -8.0%
Revenue (ttm)628.77M +16.4%
Net Income41.64M
EPS0.73
Shares Outn/a
PE Ratio131.88
Forward PE57.52
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume4
Open104.10
Previous Close111.95
Day's Range104.10 - 104.10
52-Week Range94.12 - 147.10
Betan/a
RSI48.56
Earnings DateMay 5, 2026

About Repligen

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spect... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1981
Employees 2,000
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol RGN

Financial Performance

Financial numbers in USD Financial Statements

News

Repligen to Report First Quarter 2026 Financial Results

Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 5, 2026, at 8:00 a.m. ET

1 day ago - GlobeNewsWire

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its ...

6 days ago - GlobeNewsWire

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its f...

2 months ago - GlobeNewsWire

Repligen to Report Fourth Quarter and Full Year 2025 Financial Results

Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, February 24, 2026, at 8:30 a.m. ET

2 months ago - GlobeNewsWire

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected...

3 months ago - GlobeNewsWire

Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference

WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i...

4 months ago - GlobeNewsWire

Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality Workflows

WALTHAM, Mass., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the launch of three new hi...

4 months ago - GlobeNewsWire

Repligen Corporation to Present at Evercore Healthcare Conference

WALTHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participat...

5 months ago - GlobeNewsWire

Repligen Reports Third Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its t...

6 months ago - GlobeNewsWire

Repligen to Report Third Quarter 2025 Financial Results

Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, October 28, 2025, at 8:30 a.m. ET

6 months ago - GlobeNewsWire

Repligen Corporation to Present at Upcoming September Conferences

WALTHAM, Mass., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be attending ...

8 months ago - GlobeNewsWire

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026

Repligen RGEN has been in a steady downtrend for over 1400 days. Adhishthana principles suggest the weakness is likely to continue.

9 months ago - Benzinga

Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have...

9 months ago - GlobeNewsWire

Repligen Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Financial Guidance

WALTHAM, Mass., July 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s...

9 months ago - GlobeNewsWire

Repligen to Report Second Quarter 2025 Financial Results

Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 29, 2025, at 8:30 a.m. ET

10 months ago - GlobeNewsWire

908 Devices Appoints Christopher D. Brown to its Board of Directors

BOSTON--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, ...

11 months ago - Business Wire

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

WALTHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the digital publication of ...

11 months ago - GlobeNewsWire

Repligen Corporation to Present at Upcoming May Investor Conferences

WALTHAM, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati...

1 year ago - GlobeNewsWire

Repligen Reports First Quarter 2025 Financial Results

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its ...

1 year ago - GlobeNewsWire

Repligen Appoints Jacob Johnson As Vice President Investor Relations

WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson ...

1 year ago - GlobeNewsWire

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

On Tuesday, Repligen Corporation RGEN purchased 908 Devices Inc.'s MASS desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications.

1 year ago - Benzinga

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

WALTHAM, Mass., & BOSTON--(BUSINESS WIRE)--Repligen Corporation (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (Nasdaq: MASS), a pioneer i...

1 year ago - Business Wire

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Repligen Corp RGEN released its fourth-quarter adjusted EPS of 44 cents on Tuesday, down from 48 cents a year ago but beating the consensus of 41 cents.

1 year ago - Benzinga

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET Webcast and Conference Call to Be Held Thursday, February 20, 2025, at 8:30 a.m. ET

1 year ago - GlobeNewsWire

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate i...

1 year ago - GlobeNewsWire